Brokerages Set CeriBell, Inc. (NASDAQ:CBLL) PT at $24.67

CeriBell, Inc. (NASDAQ:CBLL) has earned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $24.6667.

Several equities research analysts have commented on CBLL shares. BTIG Research restated a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, Canaccord Genuity Group lifted their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th.

CeriBell News Roundup

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Quarterly results beat expectations: CeriBell reported a narrower-than-expected loss (EPS -$0.36 vs. -$0.43 est.) and revenue topped estimates, which is a constructive fundamental data point for future guidance and valuation. MarketBeat CBLL
• Positive Sentiment: Analyst backing remains favorable: multiple firms (Canaccord, TD Cowen, BTIG) maintain Buy/Overweight stances and some have raised targets (Canaccord to $30), supporting medium-term upside relative to current levels. MarketBeat Analyst Coverage
• Neutral Sentiment: Short-interest report shows an apparent increase but the published data contains anomalies (0 shares / NaN increase and 0.0 days-to-cover), so there’s no reliable signal of a true rise in short activity at this time.
• Negative Sentiment: CEO sale: CEO Xingjuan Chao sold 39,000 shares (~$680,550 at ~$17.45), reducing his stake by ~5.2% — a large insider disposition that can be perceived negatively by the market. SEC Filing – CEO Sale
• Negative Sentiment: Other senior insider sales: CTO Raymond Woo (8,087 shares, ~$147.6k), VP David Foehr (4,560 shares, ~$81.2k) and Director Rebecca Robertson (827 shares, ~$14.7k) all sold shares in early March; multiple concurrent sales by senior execs amplify negative perception. SEC Filing – CTO Sale SEC Filing – VP Sale InsiderTrades – Director Sale

Insiders Place Their Bets

In other CeriBell news, CTO Raymond Woo sold 11,112 shares of CeriBell stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $21.18, for a total value of $235,352.16. Following the sale, the chief technology officer directly owned 167,317 shares in the company, valued at approximately $3,543,774.06. The trade was a 6.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Xingjuan Chao sold 79,000 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $21.27, for a total transaction of $1,680,330.00. Following the transaction, the chief executive officer owned 741,248 shares of the company’s stock, valued at approximately $15,766,344.96. This represents a 9.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 297,355 shares of company stock valued at $6,170,581 in the last quarter. Company insiders own 20.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. TimesSquare Capital Management LLC raised its holdings in shares of CeriBell by 48.5% in the 2nd quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock valued at $14,927,000 after purchasing an additional 260,116 shares during the period. Geode Capital Management LLC grew its holdings in CeriBell by 55.4% during the second quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock worth $8,391,000 after purchasing an additional 159,698 shares during the period. Police & Firemen s Retirement System of New Jersey grew its holdings in CeriBell by 161.0% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after purchasing an additional 3,502 shares during the period. Intech Investment Management LLC acquired a new position in CeriBell during the second quarter worth approximately $266,000. Finally, JPMorgan Chase & Co. raised its stake in CeriBell by 6,424.8% in the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after buying an additional 374,179 shares during the period.

CeriBell Price Performance

CBLL stock opened at $17.83 on Monday. The stock has a 50-day moving average price of $20.77 and a two-hundred day moving average price of $16.53. The stock has a market cap of $671.12 million, a PE ratio of -12.13 and a beta of 1.13. The company has a current ratio of 9.73, a quick ratio of 9.35 and a debt-to-equity ratio of 0.13. CeriBell has a 1 year low of $10.01 and a 1 year high of $24.33.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $24.78 million for the quarter, compared to analyst estimates of $23.95 million. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%. Equities analysts forecast that CeriBell will post -2.46 EPS for the current fiscal year.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.